The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people.
BACKGROUND
Elderly patients treated with antidepressants for depression are at high risk for injury due to falling. The primary purpose of this study was to determine the effects of amitriptyline, desipramine, and paroxetine on the gait of healthy elderly subjects during unobstructed and obstructed (i.e., stepping over obstacles) gait. Psychomotor and mood tests were also performed.


METHODS
A randomized, crossover, four-period, double-blind, placebo-controlled laboratory trial was performed. Twelve healthy elderly subjects (average age, 67 years; range, 65-72 years) were tested. Subjects were assigned the three antidepressant drugs or a placebo in a random order. Single doses of amitriptyline 50 mg, desipramine 50 mg, paroxetine 20 mg, or placebo were given 4 hours prior to gait testing. Temporal-distance measures and kinematics of the lower trailing limb (i.e., limb going over obstacle last) were obtained.


RESULTS
Compared with placebo, amitriptyline significantly reduced gait velocity by as much as 8.0% (p = .028), cadence by as much as 4.9% (p = .012), angular velocity of hip flexion by as much as 10.0% (p = .004), and angular velocity of knee flexion by as much as 8.3% (p = 018) during the crossing strides when stepping over obstacles. Except for knee flexion angle, unobstructed gait was not affected. Amitriptyline affected integrative capacity of the central nervous system (CNS) and ability to concentrate as measured by psychomotor and mood tests.


CONCLUSIONS
The results for amitriptyline suggest that the subjects slowed their obstacle crossing speeds as a result of reduced CNS integrative capacities. Neither paroxetine nor desipramine significantly affected gait, psychomotor function, or mood.
Draganich
L F
LF
Department of Surgery, The University of Chicago, Illinois 60637, USA. ldragani@surgery.bsd.uchicago.edu
Zacny
J
J
Klafta
J
J
Karrison
T
T
D000339:Affect / Q000187:drug effects; D000368:Aged; D000639:Amitriptyline / Q000009:adverse effects*; D000928:Antidepressive Agents / Q000009:adverse effects*; D003891:Desipramine / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D005684:Gait / Q000187:drug effects*; D006801:Humans; D008297:Male; D017374:Paroxetine / Q000009:adverse effects; D011597:Psychomotor Performance / Q000187:drug effects; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects
D000639:Amitriptyline; D000928:Antidepressive Agents; D003891:Desipramine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors